Bayer's Stroke Medication Achieves Trial Objectives; Analyst Anticipates Favorable Data from Bristol Myers' Milvexian Following Unsuccessful Study | Intellectia.AI
Bayer's Stroke Medication Achieves Trial Objectives; Analyst Anticipates Favorable Data from Bristol Myers' Milvexian Following Unsuccessful Study
Written by Emily J. Thompson, Senior Investment Analyst
Bayer's Phase 3 Study Results: Bayer AG announced positive topline results from the Phase 3 OCEANIC-STROKE study for its oral FXIa inhibitor asundexian, which significantly reduced the risk of ischemic stroke without increasing major bleeding risks compared to placebo.
Impact on Bristol-Myers Squibb: The positive results for asundexian are seen as beneficial for Bristol-Myers Squibb's milvexian program, especially after the recent halt of the LIBREXIA-ACS trial due to lack of efficacy.
Dosing Concerns: Analysts are questioning whether the dosing levels of milvexian being tested are optimal, particularly in light of Bayer's previous findings that indicated insufficient dosing of asundexian in a different study.
Market Reaction: Following the news, Bristol-Myers Squibb's stock rose by 4.57%, reflecting investor optimism regarding the implications of Bayer's trial results.
Wall Street analysts forecast BMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMY is 55.86 USD with a low forecast of 37.00 USD and a high forecast of 68.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
Wall Street analysts forecast BMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMY is 55.86 USD with a low forecast of 37.00 USD and a high forecast of 68.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 54.940
Low
37.00
Averages
55.86
High
68.00
Current: 54.940
Low
37.00
Averages
55.86
High
68.00
Scotiabank
Louise Chen
Sector Perform
maintain
$53 -> $60
2026-01-09
Reason
Scotiabank
Louise Chen
Price Target
$53 -> $60
AI Analysis
2026-01-09
maintain
Sector Perform
Reason
Scotiabank analyst Louise Chen raised the firm's price target on Bristol Myers to $60 from $53 and keeps a Sector Perform rating on the shares. The firm believes the upcoming year is "catalyst-rich" and its inexpensive valuation makes the stock appear attractive, the analyst tells investors.
UBS
Neutral -> Buy
upgrade
$46 -> $65
2026-01-07
Reason
UBS
Price Target
$46 -> $65
2026-01-07
upgrade
Neutral -> Buy
Reason
UBS upgraded Bristol Myers to Buy from Neutral with a price target of $65, up from $46, after assuming coverage of the name. After several challenging years, biotech and pharma are emerging from a cyclical trough, supported by improving macro conditions, stronger fundamentals, increased FDA approvals, positive clinical data, and accelerating M&A, the analyst says in a research note. Investor confidence is expected to rise in 2026, setting the stage for sector outperformance, UBS adds.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BMY
Unlock Now
Citi
Neutral
maintain
$45 -> $53
2026-01-07
Reason
Citi
Price Target
$45 -> $53
2026-01-07
maintain
Neutral
Reason
Citi raised the firm's price target on Bristol Myers to $53 from $45 and keeps a Neutral rating on the shares.
Goldman Sachs
Buy
maintain
$95 -> $99
2025-12-22
Reason
Goldman Sachs
Price Target
$95 -> $99
2025-12-22
maintain
Buy
Reason
Goldman Sachs raised the firm's price target on Cytokinetics (CYTK) to $99 from $95 and keeps a Buy rating on the shares. Cytokinetics received FDA approval for aficamten, now branded Myqorzo, to treat adults with symptomatic obstructive hypertrophic cardiomyopathy, improving functional capacity and symptoms, the analyst tells investors in a research note. The label appears marginally superior to Bristol Myers' (BMY) Camzyos and aligns with expectations for an incrementally differentiated REMS program, the firm says.
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
